Allogeneic hematopoietic cell transplantation

Allogeneic hematopoietic cell transplantation (allogeneic hematopoietic cell transplantation) is a clinical transplant procedure in which hematopoietic cells are transferred in the allogeneic setting, and it serves as a major platform for post-transplant intervention and outcome assessment. It is used in studies of post-transplant non-relapse mortality prediction, including a composite risk assessment model for allogeneic hematopoietic cell transplantation-associated outcomes. In therapeutic development, it is the setting for testing GVHD- and relapse-prevention strategies after myeloablative transplantation, including PTCy, sirolimus, and VIC-1911, and it also supports post-transplant maintenance approaches such as vcar33. Recent literature highlights a phase 1/2 donor-derived anti-CD33 CAR T-cell study in relapsed/refractory AML after allo-HCT, showing how the platform is being extended beyond conditioning into cellular maintenance and relapse control. Overall, allo-HCT remains a central clinical context for balancing graft-versus-leukemia effects against graft-versus-host disease and non-relapse mortality.

Transplant outcomes and risk prediction

  • A single-center evaluation tested a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (PMID:41951840).
  • The study frames allo-HCT as a setting where post-transplant mortality risk stratification is clinically important for outcome prediction (PMID:41951840).
  • The Key Facts emphasize post-transplant non-relapse mortality prediction as a core clinical context for this technology.
  • The model was evaluated specifically in the transplant setting rather than in a non-transplant population (PMID:41951840).

GVHD and relapse prevention

  • A 2026 Blood Advances study examined targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation (PMID:41592279).
  • The transplant platform in this work was explicitly myeloablative, indicating use in intensive conditioning regimens (PMID:41592279).
  • The study tested PTCy, sirolimus, and VIC-1911 in the allo-HCT context, linking the procedure to immunomodulatory prophylaxis strategies (PMID:41592279).
  • These findings position allo-HCT as a key setting for interventions aimed at reducing both graft-versus-host disease and relapse (PMID:41592279).

Post-transplant maintenance and cellular therapy

  • A 2026 Blood phase 1/2 study evaluated donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT (PMID:41636724).
  • vcar33 was used as post-alloHCT maintenance therapy, showing the transplant setting can support sequential cellular treatment approaches (PMID:41636724).
  • The study extends allo-HCT beyond the transplant event into post-transplant disease control for AML (PMID:41636724).
  • This application underscores the role of allo-HCT as a platform for relapse-directed immunotherapy after transplantation (PMID:41636724).